Shares of Inovio Inc. (NASDAQ:INO) fell 25% to $6.85 on April 23 after the company said the U.S. Department of Defense scratched funding for the phase III portion of an ongoing trial of its COVID-19 vaccine candidate, INO-4800, in light of the broad availability of other COVID-19 vaccines in the U.S. The news followed recent phase I data showing '4800 performed about in line with already available competitors against SARS-CoV-2 variants now dominant in the U.S.
DUBLIN – The European Medicines Agency (EMA) has reiterated its support for Astrazeneca plc’s Vaxzervia COVID-19 vaccine, following an interim analysis of a data review, which the agency’s Committee on Human Medicinal Products (CHMP) has conducted over the past two weeks.
LONDON – A large scale U.K. study looking at the impact of COVID-19 vaccinations on antibody responses and new infections in 373,402 people in the general population has shown a single dose of vaccine cut infections by 65%. Symptomatic infections fell by 74% and infections with no reported symptoms by 57%, 21 days after receiving the first dose of either Astrazeneca plc’s or Pfizer Inc./Biontech SE’s vaccine.
The CDC’s Advisory Committee on Immunization Practices again took up the matter of risk vs. benefit with the COVID-19 vaccine made by Johnson & Johnson, and proved significantly less skeptical at its second meeting. The FDA and CDC swiftly determined that the recommended pause should be lifted and use of the vaccine should resume.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbott, Cloud Dx, Dhl Holdings, Emed, Illumina, Inter Medico, Jolly Good, Kartos Therapeutics, McKesson, Premier, Quidel, Sight Diagnostics, Spacelabs Healthcare, Teijin Pharma.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, ADC, Biogen, BMS, Calliditas, Eisai, Gilead, Glaxosmithkline, Hua, Leo, Medicago, Merck, Protara, Roche, Shanghai Henlius, Shorla.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Courage, E-therapeutics, Ethypharm, Galapagos, Inovio, Life.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Arcutis, Arena, Avillion, Boehringer Ingelheim, Brickell, Bristol Myers Squibb, Eli Lilly, EMD Serona, Incyte, Janssen, Nicox, Novartis, Novavax, UCB, Verona.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Better Therapeutics, Diacarta, Elixir Medical, Solace Therapeutics.
RSS
